
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
- Volume 11
- Issue 8
DPx Holdings Sells Fine Chemicals Business
Investment group Ardian will acquire the fine chemicals business activities of DPx Holdings B.V.
Ardian, a private investment company, together with current management, announced on July 22 the acquisition of the Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) business activities of DPx Holdings B.V., based in Linz, Austria. Details of the transaction were not disclosed.
ES develops and produces chemical intermediate products for agriculture and other industries. IM produces maleic anhydride, intermediates, derivatives, and esters. The groups had a combined sales of €200 million for the 2014 financial year and 390 employees.
With the support of Ardian, the management of ES and IM plans to significantly strengthen its market position, the company reports in a statement. Investment will focus on expanding the product portfolio through organic growth, strategic acquisitions, and expanding into new markets.
DPx Holdings B.V. is the parent company of the Patheon, DPx Fine Chemicals, and Banner Life Sciences businesses.
Source:
Articles in this issue
over 10 years ago
CDMOs Move Slowly with Expansion Plansover 10 years ago
Accelerating Continuous API Synthesisover 10 years ago
BioOutsource Opens New Facility in Glasgowover 10 years ago
Silicone Rubber Pieces Spur Recall of Teva Productover 10 years ago
Baxter Recalls IV Solution for Container and Particulate Issuesover 10 years ago
Indian API Manufacturer Cited for Recordkeeping Failuresover 10 years ago
Xcelience Makes Investment in Powdersizeover 10 years ago
FDA Issues Quality Metrics Draft Guidance Document for Commentover 10 years ago
EMA Issues Guideline on Fast Tracking Drugs for Unmet NeedsNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





